SCHEMBL6865570

SCHEMBL6865570

CC1(C)OB(c2ccc(Oc3ccccc3)c(C=O)c2)OC1(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.49
GAA P10253 1/20 0.49
KMT2A Q03164 1/20 0.49
LIPG Q9Y5X9 7/20 0.44
LPL P06858 6/20 0.44
TTR P02766 1/20 0.42
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
NPSR1 Q6W5P4 1/20 0.40
P4HB P07237 1/20 0.40
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
ERN1 O75460 1/20 0.36
DGAT1 O75907 1/20 0.36
HTT P42858 1/20 0.35
CSF1R P07333 1/20 0.34
ROCK1 Q13464 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4477463 0.90 LMNA (0.49) LMNAGAAKMT2ALIPGLPL
SCHEMBL5801905 0.84 LMNA (0.57) LMNAGAAKMT2ALIPGLPL
SCHEMBL552983 0.82 CSF1R (0.45) LMNALIPGLPLALDH1A1P4HB
SCHEMBL1128900 0.81 TSHR (0.52) LMNAGAAKMT2ALIPGLPL
SCHEMBL26133310 0.81 DGAT1 (0.48) KMT2ALIPGLPLALDH1A1P4HB
SCHEMBL1129289 0.81 LIPG (0.49) LIPGLPLP4HBCA1CA2
SCHEMBL1129150 0.80 TTR (0.48) LIPGLPLTTRP4HBCA1
SCHEMBL4366318 0.80 LPL (0.47) LIPGLPLP4HBCA1CA2
SCHEMBL1129141 0.80 TTR (0.48) LIPGLPLTTRALDH1A1P4HB
SCHEMBL4356244 0.80 LPL (0.47) LIPGLPLTTRCYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6713474-B2 SERINE-THREONINE AND TYROSINE KINASE INHIBITORS ABBOTT GMBH & CO. KG (DE) 2004-03-30 US disclosed
US-20030153752-A1 Pyrrolopyrimidines as therapeutic agents ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2003-08-14 US disclosed
WO-2001072751-A1 PYRROLOPYRIMIDINES AS TYROSINE KINASE INHIBITORS KNOLL GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2001-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153752-A1 Pyrrolopyrimidines as therapeutic agents FLT1, FLT4, TFPI LMNA 4657/4885GAA 4375/4885KMT2A 2637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.